Comerica Bank Sells 22,144 Shares of Johnson & Johnson $JNJ

Key Points

• Comerica Bank cut its Johnson & Johnson stake by 2.5% in Q3, selling 22,144 shares and now holds 851,226 shares worth $157,834,000, making JNJ its 25th-largest holding (~0.6% of the bank's portfolio).
• Positive catalysts for JNJ include FDA approval of the TECNIS PureSee intraocular lens and promising Phase 1 Erda‑iDRS oncology data, and analysts have been lifting targets (Bank of America to $253), supporting a consensus "Moderate Buy" average target of about $235.91.
• Insider and institutional activity: executives sold shares recently (EVPs sold 6,197 and 1,322 shares in disclosed trades) with 30,142 insider shares sold last quarter and insiders now owning 0.16%, while institutions own roughly 69.55% of JNJ stock.

Comerica Bank decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 851,226 shares of the company's stock after selling 22,144 shares during the quarter. Johnson & Johnson comprises approximately 0.6% of Comerica Bank's investment portfolio, making the stock its 25th largest holding. Comerica Bank's holdings in Johnson & Johnson were worth $157,834,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JNJ. Abich Financial Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $26,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $28,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Semmax Financial Advisors Inc. increased its position in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after buying an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc raised its stake in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company's stock worth $42,000 after buying an additional 198 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves the TECNIS PureSee intraocular lens, adding a new, differentiated cataract/presbyopia product to J&J’s surgical vision portfolio — could support revenue and aftermarket growth in the medtech segment. FDA Approval Of TECNIS PureSee IOL Adds New Lens For J&J Investors
• Positive Sentiment: Promising Phase 1 Erda‑iDRS (erdafitinib) results in intermediate‑risk NMIBC: 89% complete response rate and durable responses up to 18 months with tolerable safety — bolsters oncology pipeline optionality if later‑stage data confirm benefit. Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
• Positive Sentiment: BofA raised its price target (to $253) and lifted revenue expectations citing pipeline growth — supportive analyst attention that can underpin sentiment even with a Neutral rating. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: Citigroup analyst expects JNJ shares to rise — additional buy-side commentary can amplify positive flows if confirmed with upgrades or higher targets. Johnson & Johnson NYSE: JNJ Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Dividend and “Dividend King” coverage reminds investors of JNJ’s income profile — supportive for long‑term holders but unlikely to drive short‑term price swings. Johnson & Johnson (JNJ) Could Be a Great Choice
• Neutral Sentiment: Barclays reaffirmed its Hold rating — steady analyst stance that tempers upside momentum from positive news. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Industry pieces on BCG shortages and competitor ImmunityBio note market dynamics in NMIBC — useful context for future demand shifts but not an immediate JNJ catalyst. IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Neutral Sentiment: Analyst / valuation updates show modest shifts in fair value assumptions tied to individual drugs (Tremfya, Tecvayli, Inlexzo, Darzalex) — indicates ongoing re‑rating risk/reward as pipeline readouts arrive. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
• Negative Sentiment: Preliminary approval of a $65M eve‑of‑trial settlement in an antitrust suit tied to Actelion’s Tracleer — modest direct financial hit but reputational/legal overhang for the pharma legacy business. Eve-of-Trial $65M Settlement Preliminarily Approved in Novel Antitrust Class Action Against J&J Subsidiary Actelion Pharmaceuticals

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. Bank of America reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. BMO Capital Markets reaffirmed an "outperform" rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Freedom Capital cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Friday, January 16th. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an "overweight" rating in a research note on Thursday, January 22nd. Finally, Daiwa Securities Group upped their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an "outperform" rating in a report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $235.91.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 1,322 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 0.1%

JNJ stock opened at $241.71 on Friday. The firm has a market capitalization of $582.50 billion, a PE ratio of 21.87, a P/E/G ratio of 2.39 and a beta of 0.34. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The stock's 50 day moving average is $231.91 and its 200-day moving average is $206.23.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion during the quarter. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson's dividend payout ratio is currently 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.